Germinoma other imaging findings: Difference between revisions

	Germinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Differentiating Germinoma from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Germinoma other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Germinoma other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA onGerminoma other imaging findings
CDC on Germinoma other imaging findings
Germinoma other imaging findings in the news
on Germinoma other imaging findings
Directions to Hospitals Treating Germinoma
Risk calculators and risk factors for Germinoma other imaging findings

VisualWikitext

Latest revision as of 23:35, 26 November 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Other diagnostic studies for germinoma include PET scan.^[1]

Other Imaging Findings

Studies have reported that 18F-fluorodeoxyglucose PET(FDG-PET) was able to detect the presence of germinomas while 11C-methionine PET (MET-PET) can help define tumor contour to plan for biopsy or surgery.^[1]

References

↑ ^1.0 ^1.1 Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y; et al. (2014). "Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system". Ann Nucl Med. 28 (2): 94–102. doi:10.1007/s12149-013-0787-4. PMC 3926980. PMID 24272066.

Template:WikiDoc Sources

[pmid24272066-1] 1.0 ^1.1 Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y; et al. (2014). "Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system". Ann Nucl Med. 28 (2): 94–102. doi:10.1007/s12149-013-0787-4. PMC 3926980. PMID 24272066.

[1]

@@ Line 3: / Line 3: @@
 {{CMG}}{{AE}}{{Simrat}}
 ==Overview==
+Other diagnostic studies for germinoma include [[PET scan]].<ref name="pmid24272066">{{cite journal| author=Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y et al.| title=Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system. | journal=Ann Nucl Med | year= 2014 | volume= 28 | issue= 2 | pages= 94-102 | pmid=24272066 | doi=10.1007/s12149-013-0787-4 | pmc=PMC3926980 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24272066  }} </ref>
 ==Other Imaging Findings==
-[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings on [diagnostic study] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
+Studies have reported that 18F-fluorodeoxyglucose PET(FDG-PET) was able to detect the presence of germinomas while 11C-methionine PET (MET-PET) can help define tumor contour to plan for [[biopsy]] or surgery.<ref name="pmid24272066">{{cite journal| author=Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y et al.| title=Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system. | journal=Ann Nucl Med | year= 2014 | volume= 28 | issue= 2 | pages= 94-102 | pmid=24272066 | doi=10.1007/s12149-013-0787-4 | pmc=PMC3926980 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24272066  }} </ref>
-===Biopsy===
-*According to the current recommendations, surgical biopsy for histological confirmation is necessary for all patients with pineal and suprasellar tumors, which is accomplished by means of endoscopic/stereotactic biopsy or open biopsy.
-*In comparison to pineal tumors suprasellar tumors are generally more accessible to surgical biopsy.
-*Adequate specimen size is important in the diagnosis because in nongerminomatous germ cell tumors (NGGCT), a specimen that is too small may miss a tumor component and thus may not be representative of the actual tumor type.
-*Histologic examination is needed to ascertain the histologic subtype and to establish a definitive diagnosis of an intracranial germ cell tumors (GCT). A tissue sample should be obtained unless surgery cannot be performed safely. Surgery to obtain a tissue sample for diagnosis is mandatory for patients with normal CSF and serum AFP and beta-hCG, as a mature teratoma or pure germinoma must be distinguished from other benign and malignant lesions.
-*Only patients with elevated CSF or serum levels of AFP or β-hCG >50-100 IU/ml do not need surgery for the purpose of tissue diagnosis. Diagnosis without tissue biopsy should be considered in the patients with secreting tumors because high postoperative mortality has been reported after resection of such tumors.
-*An elevated level of AFP in either the CSF or serum is sufficient to classify a tumor as a NGGCT, although tumor tissue is useful for prognostic classification. Patients with a normal AFP but an elevated beta-hCG (>50 IU/L) should undergo surgery if possible to distinguish an immature teratoma or a choriocarcinoma from beta-hCG secreting germinoma, as the former are considered NGGCTs and need more aggressive treatment.
 ==References==
 {{Reflist|2}}
@@ Line 24: / Line 18: @@
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}
+ [[Category:Up-To-Date]]
+[[Category:Oncology]]
+[[Category:Medicine]]
+[[Category:Neurology]]
+[[Category:Neurosurgery]]

Germinoma other imaging findings: Difference between revisions

Latest revision as of 23:35, 26 November 2017

Overview

Other Imaging Findings

References

Navigation menu